IRD today

$4.31+$0.08 (+1.89%)close Nov 11, 2026

Trend

DailyUptrend (starting)

4 hourStrong Bullish

1 hourLeaning Bearish

15 minBearish

5 minStrong Bullish

Daily trend turns down below $2.82

Key levels

Resistance$4.88

Resistance$4.37

Support$3.69

Support$3.23

About Opus Genetics

Opus Genetics develops gene-based medicines for inherited retinal diseases and other eye conditions. Its pipeline includes AAV gene therapy candidates for LCA5-related and BEST1-related retinal degeneration, along with earlier-stage programs addressing several other genetic forms of retinal disease. The company also develops Phentolamine Ophthalmic Solution 0.75%, an eye drop approved for pharmacologically induced mydriasis and being studied for presbyopia and low-light visual disturbances after keratorefractive surgery. It operates mainly in the United States and works with partners such as Viatris to commercialize its products in most markets worldwide.

Based on the company's 10-K filed Mar 12, 2026.

Nasdaq · Healthcare

Opus Genetics, Inc. (IRD)

$4.31+0.08 (+1.89%)

WATCHLISTGrade: BRisk: MEDIUM

1D 5D1M1Y 5Y MaxSign up for all timeframes

High4.52

Low4.13

Open4.31

Volume1.19M

Avg Vol1.42M

VWAP4.34

30d High4.65

30d Low3.32

30d Chg-4.43%

See full chart with real-time data

What Is the Price Target for IRD?

SEPT Low Target

$8.00

SEPT Mid Target

$13.50

SEPT High Target

$20.00

Analyst Consensus

$13.50

Current: $4.31Upside: +213.2%Confidence: 85%Method: Analyst Consensus

Is IRD a Buy or Sell Right Now?

Investability Score

WATCHLIST12-18 months

News summary · last 30 days

Nov 11▲ UpUpgrade2 articles

Opus Genetics (IRD) shares closed flat at $4.31, though the stock traded in a wide range between $4.13 and $4.52 on elevated volume of about 1.19 million shares. The session's key catalyst was RBC Capital reiterating its Outperform rating and raising its price target to $11 from $9, signaling increased analyst confidence in the biotech. Despite the bullish analyst action, the stock failed to hold its intraday high and finished unchanged, suggesting the upgrade was already partly priced in or offset by broader selling pressure. The raised target implies significant upside from current levels, a constructive signal for the direction of the shares.

Oct 21▲ UpFda approval successLeadership3 articles

Opus Genetics shares closed at $4.12, up 2.11% on volume of 1,231,494, after the FDA cleared the company's IND application for OPGX-RDH12, an investigational gene therapy for RDH12-associated Leber congenital amaurosis. The clearance allows Opus to move forward with clinical development of the treatment, a bullish catalyst with medium impact. The company also filed a Form 8-K disclosing a major company event, though details were not specified and the item was assessed as neutral with low impact. The FDA news likely drove the positive price action, with the stock trading between $4.00 and $4.21 on the day.

Thesis

•Revenue growing 29.1% YoY with ACCELERATING trend — accelerating momentum.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IRD.

Start Free Trial →

Is IRD Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

Analyst Consensus

Fair Value

$13.50

Moat Score

NONE

3/9

Piotroski Score

-2.0

Altman Z-Score

What Is Smart Money Doing with IRD?

Insider Signal

SELLING

0 buys / 17 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Recent Insider Activity

Name	Title	Type	Shares	Value	Date
Magrath George	director officer	Sale	28,258	$110K	Nov 3, 2026
SCHACHLE JOSEPH K	officer	Sale	4,767	$17K	Oct 23, 2026
YERXA BENJAMIN R	director officer	Sale	7,669	$27K	Oct 23, 2026
YERXA BENJAMIN R	director officer	Sale	25,520	$90K	Oct 23, 2026
Gagnon Robert E.	officer	Sale	14,000	$50K	Oct 23, 2026
Magrath George	director officer	Sale	9,591	$34K	Oct 23, 2026
Magrath George	director officer	Buy	392,157	$451K	Sep 9, 2026
Magrath George	director officer	Sale	75,541	$451K	Sep 9, 2026
Foundation Fighting Blindness Retinal Degeneration Fund	director	Sale	1,700,000	$7.4M	May 18, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

IRD Growth Story

Revenue YoY

29.1%

3yr Revenue CAGR

-29.1%

EPS Growth YoY

62.79%

FCF Growth YoY

N/A%

Revenue Trend

ACCELERATING

Dark Pool Trades for IRD

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for IRD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
21:00:22	$4.31	6,454	$$28K	SELL
21:00:01	$4.31	2,900	$$12K	SELL
20:51:11	$4.33	1,616	$$7K	BUY
20:50:19	$4.34	2,305	$$10K	SELL
19:53:21	$4.52	1,000	$$5K	SELL

5 dark pool trades shown · $$62K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Options Flow for IRD

PREVIEW

SEPT Investing provides real-time options flow tracking for IRD, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.

Type	Strike	Expiry	DTE	Premium	Size	Trade
CALL	$5	Nov 20	9	$$5	1	SWEEP
CALL	$5	Nov 20	9	$$5	1	SWEEP
CALL	$5	Nov 20	9	$$5	1	SWEEP
CALL	$5	Nov 20	9	$$5	1	SWEEP
CALL	$5	Nov 20	9	$$5	1	SWEEP

5 options trades shown · 100% calls

Unusual activity, GEX levels, max pain, and dealer positioning

See full options flow

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Opus Genetics, Inc. (IRD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

IRD — frequently asked questions

What is IRD stock price today?

Opus Genetics, Inc. (IRD) is at $4.31, up 1.89% (+$0.08) at the Nov 11, 2026 close.

Why is IRD stock up today?

Nov 11, 2026: Opus Genetics (IRD) shares closed flat at $4.31, though the stock traded in a wide range between $4.13 and $4.52 on elevated volume of about 1.19 million shares. The session's key catalyst was RBC Capital reiterating its Outperform rating and raising its price target to $11 from $9, signaling increased analyst confidence in the biotech.

What is the IRD price target?

The average analyst price target for IRD is $13.50, ranging from $8 to $20, based on 12 analysts. Latest: HC Wainwright & Co. maintains on Nov 11, 2026.

What do analysts rate IRD?

Analyst ratings for IRD: 0 Buy, 17 Hold, 0 Sell — consensus Hold.

Did IRD beat earnings?

IRD last reported on Nov 11, 2026: EPS -$0.46 vs -$0.15 expected — a miss of 206.7%.

Does IRD pay a dividend?

IRD does not currently pay a dividend.

How much debt does IRD have?

Opus Genetics, Inc. reported $35M of debt and $89M of cash (Jun 30, 2026).

What are IRD support and resistance levels?

Support: $3.69, $3.23, $2.82. Resistance: $4.37, $4.88, $5.32.

What are insiders doing with IRD?

Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.

What is the latest news on IRD?

Nov 11, 2026: RBC Capital keeps Outperform rating on Opus Genetics, lifts target to $11 · Nov 11, 2026: RBC Raises Opus Genetics Target to $11 From $9 · Nov 11, 2026: HC Wainwright keeps Buy rating on Opus Genetics, lifts target to $14